Search Results - Machuron, V.

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    EPH4 Burden and Characteristics of COVID-19 in France During 2020 Based on National Hospital Database

    EPH4 Burden and Characteristics of COVID-19 in France During 2020 Based on National Hospital Database by Leboucher, C, Blein, C, Machuron, V, Le Lay, K, Benyounes, K, Millier, A, Raffi, F

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    EPH64 Public Health Impact of COVID-19 in French Ambulatory Patients With at Least One Risk Factor for Severe Disease

    EPH64 Public Health Impact of COVID-19 in French Ambulatory Patients With at Least One Risk Factor for Severe Disease by Supiot, R, Millier, A, Benyounes, K, Machuron, V, Le Lay, K, Sivignon, M, Leboucher, C, Blein, C, Raffi, F

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    PCN277 Analysis of Treatment Sequences in HER2-Positive EARLY Breast Cancer Patients: A Retrospective Study from the French National Hospital Database Using a Machine Learning Algorithm, the TAK

    PCN277 Analysis of Treatment Sequences in HER2-Positive EARLY Breast Cancer Patients: A Retrospective Study from the French National Hospital Database Using a Machine Learning Algo... by Laurent, M., Prodel, M., Vainchtock, A., Gilberg, M., Ghorbal, R., Machuron, V., Tehard, B., Dupin, J.

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    PCN525 FIRST VALUE-BASED PRICE AGREEMENT IN FRANCE BASED ON PRM REAL-WORLD DATA

    PCN525 FIRST VALUE-BASED PRICE AGREEMENT IN FRANCE BASED ON PRM REAL-WORLD DATA by Cozzone, D., Samelson, L., Machuron, V., Da Costa, J., Tehard, B., Pinguet, J.M.

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    The Personalised Reimbursement Models (Prm): Real World Data Collection to Provide Innovative Pricing Solutions in France

    The Personalised Reimbursement Models (Prm): Real World Data Collection to Provide Innovative Pricing Solutions in France by Doly, A, Coudert, B, Cottu, P, Manson, J, Barletta, H, Perol, D, Aujoulat, O, Azria, D, Pivot, X, Montastier, R, Grandfils, N, Pinguet, J, Machuron, V, Samelson, L, Tehard, B

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    PRM72 - The Personalised Reimbursement Models (Prm): Real World Data Collection to Provide Innovative Pricing Solutions in France

    PRM72 - The Personalised Reimbursement Models (Prm): Real World Data Collection to Provide Innovative Pricing Solutions in France by Doly, A, Coudert, B, Cottu, P, Manson, J, Barletta, H, Perol, D, Aujoulat, O, Azria, D, Pivot, X, Montastier, R, Grandfils, N, Pinguet, J, Machuron, V, Samelson, L, Tehard, B

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Intrauterine balloon tamponade in the management of severe postpartum haemorrhage after vaginal delivery: Is the failure early predictable?

    Intrauterine balloon tamponade in the management of severe postpartum haemorrhage after vaginal delivery: Is the failure early predictable? by Leleu, A., Ghesquiere, L., Machuron, F., Caudrelier, C., Devouge, P., Subtil, D., Houflin-Debarge, V., Garabedian, C.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    PO-41: Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?

    PO-41: Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial? by Petit, B., Soudet, S., Poenou, G., Zarrat, E., Machuron, T., Accassat, S., Plaisance, L., Helfer, H., Mismetti, V., Le Hello, C., Sevestre, M.-A., Mahé, I., Bertoletti, L.

    Published in Thrombosis research
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?

    Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial? by Petit, B., Soudet, S., Poenou, G., Zarrat, E., Machuron, T., Accassat, S., Plaisance, L., Helfer, H., Mismetti, V., Le Hello, C., Pietri-Sevestre, Marie-Antoinette, Mahe, I., Bertoletti, L.

    Published in Thrombosis research
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    TEMPORARY REMOVAL: PO-41: Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?

    TEMPORARY REMOVAL: PO-41: Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial? by Petit, B, Soudet, S, Poenou, G, Zarrat, E, Machuron, T, Accassat, S, Plaisance, L, Helfer, H, Mismetti, V, Le Hello, C, Sevestre, M-A, Mahé, I, Bertoletti, L

    Published in Thrombosis research
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: